In this analysis of a large cohort of NSCLC patients with KRAS mutant tumours, we observed co-occurring KRAS mutations in 8% of the KRAS c.34G>T mutant NSCLC tumours, of which KRAS c.35G>T was most frequently detected. The gene discussed is KRAS; the disease is neoplasm.